Can Fite Biopharma (CANF) Given a $7.00 Price Target at Maxim Group

Can Fite Biopharma (NYSEAMERICAN:CANF) has been assigned a $7.00 price target by equities research analysts at Maxim Group in a report issued on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price would suggest a potential upside of 268.42% from the stock’s previous close.

The analysts wrote, “Weeks after the announcement of enrollment of the first patient in the P3 ACRobat study of Piclidenoson in RA, Can-Fite has announced a distribution agreement with Gebro Holdings GmBH for distribution in Spain, Switzerland, and Austria upon regulatory approval.””

Separately, HC Wainwright restated a “buy” rating on shares of Can Fite Biopharma in a research note on Tuesday, October 31st.

Can Fite Biopharma (NYSEAMERICAN CANF) opened at $1.90 on Monday. The firm has a market capitalization of $25.30, a price-to-earnings ratio of 6.24 and a beta of 1.37. Can Fite Biopharma has a 52-week low of $1.24 and a 52-week high of $2.67.

WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

What are top analysts saying about Can Fite Biopharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Can Fite Biopharma and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit